Abstract: Provided herein are antioxidant-enriched multivitamin compositions comprising vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folic acid, vitamin B 12, biotin, pantothenic acid, zinc, selenium, coenzyme Q10, lutein, lycopene, and zeaxanthin for the treatment of fat malabsorption diseases such as cystic fibrosis. Also provided are methods of treating vitamin and micronutrient deficiencies in subjects suffering from cystic fibrosis by administering an antioxidant-enriched multivitamin composition.

Abstract: A scalable vitamin composition unit dosage adapted to treat a fat-soluble vitamin deficiency in a subject is provided herein, the unit dosage consisting essentially of vitamin D, vitamin E, vitamin K, and vitamin A, wherein the unit dosage is substantially free of additional vitamins and wherein the unit dosage is scalable based on the weight, age, and condition of a subject without inducing toxic effects. Also provided are methods of treating a fat-soluble vitamin deficiency in a subject in need thereof by administering to the subject an effective amount of a unit dosage as described herein.

Abstract: A scalable vitamin composition unit dosage adapted to treat a fat-soluble vitamin deficiency in a subject is provided herein, the unit dosage consisting essentially of vitamin D, vitamin E, vitamin K, and vitamin A, wherein the unit dosage is substantially free of additional vitamins and wherein the unit dosage is scalable based on the weight, age, and condition of a subject without inducing toxic effects. Also provided are methods of treating a fat-soluble vitamin deficiency in a subject in need thereof by administering to the subject an effective amount of a unit dosage as described herein.

Abstract: Provided herein are antioxidant-enriched multivitamin compositions comprising vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folic acid, vitamin B 12, biotin, pantothenic acid, zinc, selenium, coenzyme Q10, lutein, lycopene, and zeaxanthin for the treatment of fat malabsorption diseases such as cystic fibrosis. Also provided are methods of treating vitamin and micronutrient deficiencies in subjects suffering from cystic fibrosis by administering an antioxidant-enriched multivitamin composition.

Abstract: A scalable vitamin composition unit dosage adapted to treat a fat-soluble vitamin deficiency in a subject is provided herein, the unit dosage consisting essentially of vitamin D, vitamin E, vitamin K, and vitamin A, wherein the unit dosage is substantially free of additional vitamins and wherein the unit dosage is scalable based on the weight, age, and condition of a subject without inducing toxic effects. Also provided are methods of treating a fat-soluble vitamin deficiency in a subject in need thereof by administering to the subject an effective amount of a unit dosage as described herein.

Abstract: The present invention relates to methods for the prevention and treatment of a mammal from radiation-induced internal injury using ?-tocotrienol, ?-tocopherol succinate or ?-tocotrienol succinate. Specifically, the present invention relates to methods for preventing and treating radiation-induced injuries in a mammal by (1) subcutaneous, intramuscular, intraperitoneal, or intravascular injection of a therapeutically effective amount of ?-tocotrienol; or (2) oral administration of a therapeutically effective amount of ?-tocopherol succinate or ?-tocotrienol succinate or both.

Abstract: The present invention relates to methods for the prevention and treatment of a mammal from radiation-induced internal injury using ?-tocotrienol, ?-tocopherol succinate or ?-tocotrienol succinate. Specifically, the present invention relates to methods for preventing and treating radiation-induced injuries in a mammal by (1) subcutaneous, intramuscular, intraperitoneal, or intravascular injection of a therapeutically effective amount of ?-tocotrienol; or (2) oral administration of a therapeutically effective amount of ?-tocopherol succinate or ?-tocotrienol succinate or both.

Abstract: A liquid Vitamin E TPGS concentrate composition is provided, the concentrate having a significantly higher percentage of TPGS per unit volume than traditional liquid TPGS formulations while providing the TPGS in a liquid form that can be used in softgels or mixed with water to produce desired concentrations for commercial use in supplements, beverages, pharmaceutical preparations, etc.

Abstract: The invention provides a composition for protecting islet cells during isolation and transplantation, as well as a method for increasing survival of islets and islet cells during harvest from the donor pancreas, isolation and culture, transportation, and transplantation into the recipient. The composition provides at least one Vitamin E homolog that, when combined with cell culture media, increases islet cell survival.

Abstract: The invention relates to novel vitamin compositions having increased absorption and bioavailability. Vitamin E compositions are provided, for example, having biologically significant amounts of one or more vitamin E homologues in an aqueous formulation. Also provided is a method for preparing aqueous formulations of lipophilic nutrients.

Abstract: Disclosed herein is an aqueous emulsion. The lipid phase of the emulsion includes a blend of a therapeutically effective concentration of a lipophile, a concentration of Vitamin E TPGS, and a concentration of linoleic acid. The presence of linoleic acid increases the solubilizing affect of Vitamin E TPGS on the lipophile and thus reduces the amount of Vitamin E TPGS that would otherwise be required in the aqueous emulsion.

Abstract: A process of forming a d-tocotrienols from a (2S) 2-hydroxymethyl-6-hydroxy-alkylchroman compound, through reaction with a farnesyl Grignard or sulfone compound. Various methods of making the (2S) 2-hydroxymethyl-6-hydroxy-alklychroman compound are disclosed.

Abstract: A process of forming a d-tocotrienol from a (2S)-vinylchromane compound, through hydroboration of the (2S)-vinylchromane to provide an organoborane, followed by coupling the organoborane with a halogenated C-14 sidechain compound under conditions of palladium-catalyzed cross-coupling is taught. Methods for providing the (2S)-vinylchromane compound and the halogenated C-14 compound are disclosed.

Abstract: A method for reducing inflammation in inflammatory bowel disease is disclosed. The method comprises reducing the expression of endothelial cell adhesion molecules in the vasculature of the bowel wall by administering a therapeutic dosage of an effective amount of a blend of vitamin E TPGS and gamma-tocopherol. Gamma-tocopherol is also useful when used alone in the invention. The reduction in endothelial cell adhesion molecules is due to the deactivation of endothelial NF?-B by the composition.

Abstract: A therapy for decreasing the rate of demyelination in multiple sclerosis comprising administering gamma-tocopherol and/or gamma-tocotrienol in a therapeutically effective dosage. The therapeutic dosage is high, between about 800 mg to about 10 grams of gamma-tocopherol and between about 50 mg to about 5 grams of gamma-tocotrienol per day.

Abstract: Disclosed herein is an aqueous emulsion of alpha-tocopherol and preferably other forms of vitamin E, coenzyme Q10, beta-carotene, vitamin D, and vitamin K useful for treating complications of cystic fibrosis. The aqueous emulsion improves malabsorption and immunity against infection, and reduces oxidative stress and respiratory complications in cystic fibrosis.

Abstract: Disclosed herein is a method of preventing or retarding the progression of diabetic microvascular and macrovascular complications by chronically administering a therapeutically effective amount of gamma-tocopherol to a diabetic patient. It is further disclosed that a greater cytoprotective benefit is provided by administering a blend of gamma-tocotrienol and alpha-tocotrienol.

Abstract: Disclosed herein is an aqueous emulsion of gamma-tocopherol and preferably other forms of vitamin E, coenzyme Q10, beta-carotene, vitamin D, and vitamin K useful for treating complications of cystic fibrosis. The aqueous emulsion improves malabsorption and immunity against infection, and reduces oxidative stress and respiratory complications in cystic fibrosis.

Abstract: Disclosed herein is an aqueous emulsion of coenzyme Q10 and preferably vitamin E, beta-carotene, vitamin D, and vitamin K useful for treating complications of cystic fibrosis. The aqueous emulsion improves malabsorption and immunity against infection, and reduces oxidative stress and respiratory complications in cystic fibrosis.